United States - English - NLM (National Library of Medicine)

pharmacia & upjohn company llc - alprazolam (unii: yu55mq3izy) (alprazolam - unii:yu55mq3izy) - alprazolam 0.25 mg - xanax is indicated for the: xanax is contraindicated in patients: there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to psychiatric medications, including xanax, during pregnancy. healthcare providers are encouraged to register patients by calling the national pregnancy registry for psychiatric medications at 1-866-961-2388 or visiting online at https://womensmentalhealth.org/research/pregnancyregistry/. neonates born to mothers using benzodiazepines late in pregnancy have been reported to experience symptoms of sedation and/or neonatal withdrawal [see warnings and precautions (5.8) and clinical considerations)] . available data from published observational studies of pregnant women exposed to benzodiazepines do not report a clear association with benzodiazepines and major birth defects (see data ). the background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adve

United States - English - NLM (National Library of Medicine)

pharmacia & upjohn company llc - alprazolam (unii: yu55mq3izy) (alprazolam - unii:yu55mq3izy) - alprazolam 0.5 mg - xanax xr is indicated for the treatment of panic disorder with or without agoraphobia, in adults. xanax xr is contraindicated in patients: there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to psychiatric medications, including xanax xr, during pregnancy. healthcare providers are encouraged to register patients by calling the national pregnancy registry for psychiatric medications at 1-866-961-2388 or visiting online at https://womensmentalhealth.org/pregnancyregistry/. neonates born to mothers using benzodiazepines late in pregnancy have been reported to experience symptoms of sedation and/or neonatal withdrawal [see warnings and precautions (5.8), and clinical considerations)] . available data from published observational studies of pregnant women exposed to benzodiazepines do not report a clear association with benzodiazepines and major birth defects (see data ). the background risk of major birth defects and miscarriage for the indicated population is unknown. all pre

United States - English - NLM (National Library of Medicine)

pharmacia & upjohn company llc - triazolam (unii: 1hm943223r) (triazolam - unii:1hm943223r) - triazolam 0.25 mg - halcion is indicated for the short-term treatment of insomnia (generally 7 to 10 days) in adults. halcion is contraindicated in: pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to psychiatric medications, including halcion, during pregnancy. healthcare providers are encouraged to register patients by calling the national pregnancy registry for psychiatric medications at 1-866-961-2388 or visiting online at https://womensmentalhealth.org/pregnancyregistry/ risk summary neonates born to mothers using benzodiazepines late in pregnancy have been reported to experience symptoms of sedation and/or neonatal withdrawal [see warnings and precautions (5.10) and ]. available data from published observational studies of pregnant women exposed to benzodiazepines do not report a clear association with benzodiazepines and major birth defects (see ) . the background risk of major birth defects and miscarriage for the indicated population is unknown. all pr

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - mitozantrone hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - rifabutin, quantity: 150 mg - capsule, hard - excipient ingredients: microcrystalline cellulose; sodium lauryl sulfate; magnesium stearate; silicon dioxide; iron oxide red; titanium dioxide; gelatin; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; simethicone; ethanol; shellac; sulfuric acid; povidone; tert-butyl alcohol; sodium hydroxide - mycobutin is indicated for: the prophylaxis of m.avium-intracellulare complex (mac) infections in patients with advanced hiv infection (cd4 counts lower than 200/ul); the treatment of infections caused by mac and other atypical mycobacteria, including in immunocompromised patients; the treatment of chronic multi-drug resistant pulmonary tuberculosis in the presence of rifampicin resistant, rifabutin-sensitive m.tuberculosis strains; the treatment of newly diagnosed pulmonary tuberculosis in the presence of rifampicin resistant, rifabutin sensitive m.tuberculosis strains. in accordance with the commonly accepted criteria for the treatment of mycobacterial infections, mycobutin should always be given in combination with other anti-mycobacterial drugs not belonging to the family of rifamycins.

Egypt - English - EDA (Egyptian Drug Authority)

pharmacia & upjohn-scientific office - sustained release tablets - 0.5 mg

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

upjohn (malaysia) sdn. bhd. - phenytoin sodium -

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

pharmacia upjohn, united states - clindamycin phosphate - lotion - 1 %

Egypt - English - EDA (Egyptian Drug Authority)

pharmacia & upjohn company, a division of pfizer inc., u.s.a. - selamectin 60mg/ml - topical solution

Egypt - English - EDA (Egyptian Drug Authority)

pharmacia & upjohn company, a division of pfizer inc., u.s.a. - selamectin 120mg/ml - topical solution